Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
D 7.23 -3.86% -0.29
IMGN closed down 3.86 percent on Monday, April 19, 2021, on 35 percent of normal volume.
Earnings due: Apr 29
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical IMGN trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish -6.10%
Doji - Bearish? Reversal -6.10%
Up 3 Days in a Row Strength -6.10%
Oversold Stochastic Weakness -6.10%
Slingshot Bearish Bearish Swing Setup -5.12%
Lower Bollinger Band Walk Weakness -5.12%
Oversold Stochastic Weakness -5.12%
Stochastic Buy Signal Bullish -0.55%
Lower Bollinger Band Walk Weakness -0.55%
Lower Bollinger Band Touch Weakness -0.55%
Older End-of-Day Signals for IMGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
Down 3% about 17 hours ago
Down 2 % about 17 hours ago
Down 1% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ImmunoGen, Inc. Description

ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Solid Tumors Drugs Monoclonal Antibodies Lymphoma Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Ovarian Cancer Non Small Cell Lung Cancer Multiple Myeloma Medical Research Her2 Antibody Drug Conjugates Chronic Lymphocytic Leukemia Lymphocytic Leukemia Acute Lymphoblastic Leukemia Cancer Therapeutics Clinical Trial Product Hematological Malignancies Immunogen Metastatic Breast Cancer Mesothelin B Cell Acute Lymphoblastic Leukemia Metastatic Small Cell Lung Cancer

Is IMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.88
52 Week Low 3.38
Average Volume 2,377,024
200-Day Moving Average 6.09
50-Day Moving Average 8.46
20-Day Moving Average 7.93
10-Day Moving Average 7.58
Average True Range 0.43
ADX 15.93
+DI 19.82
-DI 29.58
Chandelier Exit (Long, 3 ATRs ) 7.53
Chandelier Exit (Short, 3 ATRs ) 8.30
Upper Bollinger Band 8.79
Lower Bollinger Band 7.07
Percent B (%b) 0.09
BandWidth 21.67
MACD Line -0.29
MACD Signal Line -0.23
MACD Histogram -0.0579
Fundamentals Value
Market Cap 1.36 Billion
Num Shares 188 Million
EPS -1.19
Price-to-Earnings (P/E) Ratio -6.08
Price-to-Sales 10.59
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.70
Resistance 3 (R3) 7.73 7.62 7.62
Resistance 2 (R2) 7.62 7.50 7.60 7.59
Resistance 1 (R1) 7.42 7.43 7.37 7.39 7.57
Pivot Point 7.31 7.31 7.28 7.29 7.31
Support 1 (S1) 7.11 7.19 7.06 7.08 6.89
Support 2 (S2) 7.00 7.12 6.98 6.87
Support 3 (S3) 6.80 7.00 6.84
Support 4 (S4) 6.77